Ayodeji Adegunsoye1, Justin M Oldham2, Carley Demchuk3, Steven Montner4, Rekha Vij2, Mary E Strek2. 1. Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, 5841 S. Maryland Avenue, Chicago IL 60637, USA. Electronic address: deji@uchicago.edu. 2. Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, 5841 S. Maryland Avenue, Chicago IL 60637, USA. 3. Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, Chicago IL 60637, USA. 4. Department of Radiology, The University of Chicago, 5841 S. Maryland Avenue, Chicago IL 60637, USA.
Abstract
BACKGROUND: Hypersensitivity pneumonitis (HP), an immune-mediated inflammatory interstitial lung disease (ILD), can result from exposure to several well-recognized antigens. Despite antigen avoidance, progressive pulmonary fibrosis and death can occur, suggesting that additional factors may contribute to disease activity. We hypothesized that the presence of autoimmunity might impact clinical course in patients with HP. In this study, we examined an HP cohort to identify those with HP and autoimmune features (HPAF), and determine its prevalence and outcomes. METHODS: The University of Chicago ILD registry was screened to identify patients with HP. Patients were characterized as HPAF if they had an autoimmune disease or features of autoimmunity, defined as the presence of specific connective tissue disease (CTD) symptoms and serologies. Demographics, clinical characteristics, and outcomes were compared between groups. Survival analysis was performed using Cox regression to identify predictors of transplant-free survival in this cohort. RESULTS: One hundred twenty patients with chronic, fibrotic HP were identified. Of these, 18/120 (15%) were characterized as HPAF. Compared to those without evidence of autoimmunity, patients with HPAF had a higher proportion of females (54% vs. 83%, respectively; p = 0.02) but were otherwise similar with regard to clinical characteristics. The presence of autoimmunity was an independent predictor of increased mortality (HR 4.45; 95% CI 1.43-13.88; p = 0.01) after multivariable adjustment. CONCLUSIONS: Fifteen percent of patients with chronic, fibrotic HP displayed evidence of a concurrent defined autoimmune disease or autoimmune features suggestive of CTD. The presence of autoimmunity in patients with chronic, fibrotic HP may portend a poorer prognosis. Future studies are needed to validate these findings and determine the impact of immunosuppressive treatment.
BACKGROUND:Hypersensitivitypneumonitis (HP), an immune-mediated inflammatory interstitial lung disease (ILD), can result from exposure to several well-recognized antigens. Despite antigen avoidance, progressive pulmonary fibrosis and death can occur, suggesting that additional factors may contribute to disease activity. We hypothesized that the presence of autoimmunity might impact clinical course in patients with HP. In this study, we examined an HP cohort to identify those with HP and autoimmune features (HPAF), and determine its prevalence and outcomes. METHODS: The University of Chicago ILD registry was screened to identify patients with HP. Patients were characterized as HPAF if they had an autoimmune disease or features of autoimmunity, defined as the presence of specific connective tissue disease (CTD) symptoms and serologies. Demographics, clinical characteristics, and outcomes were compared between groups. Survival analysis was performed using Cox regression to identify predictors of transplant-free survival in this cohort. RESULTS: One hundred twenty patients with chronic, fibrotic HP were identified. Of these, 18/120 (15%) were characterized as HPAF. Compared to those without evidence of autoimmunity, patients with HPAF had a higher proportion of females (54% vs. 83%, respectively; p = 0.02) but were otherwise similar with regard to clinical characteristics. The presence of autoimmunity was an independent predictor of increased mortality (HR 4.45; 95% CI 1.43-13.88; p = 0.01) after multivariable adjustment. CONCLUSIONS: Fifteen percent of patients with chronic, fibrotic HP displayed evidence of a concurrent defined autoimmune disease or autoimmune features suggestive of CTD. The presence of autoimmunity in patients with chronic, fibrotic HP may portend a poorer prognosis. Future studies are needed to validate these findings and determine the impact of immunosuppressive treatment.
Authors: S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Michelle C Rocha; Leonilda M B Santos; Ericson Bagatin; Jan W Cohen Tervaert; Jan G M C Damoiseaux; Alessandro V Lido; Ana L Longhini; Cristiane O Torello; Mary L S Queiroz Journal: Int J Hyg Environ Health Date: 2011-12-05 Impact factor: 5.840
Authors: M P Webber; W Moir; R Zeig-Owens; M S Glaser; N Jaber; C Hall; J Berman; B Qayyum; K Loupasakis; K Kelly; D J Prezant Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Tracy J Doyle; Paul F Dellaripa; Kerri Batra; Michelle L Frits; Christine K Iannaccone; Hiroto Hatabu; Mizuki Nishino; Michael E Weinblatt; Dana P Ascherman; George R Washko; Gary M Hunninghake; Augustine M K Choi; Nancy A Shadick; Ivan O Rosas Journal: Chest Date: 2014-07 Impact factor: 9.410
Authors: Murray B Urowitz; Dafna D Gladman; Dominique Ibañez; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Anne E Clarke; Sasha Bernatsky; Paul R Fortin; John G Hanly; David Isenberg; Anisur Rahman; Daniel J Wallace; Ellen Ginzler; Michelle Petri; Ian N Bruce; Joan T Merrill; Ola Nived; Gunnar Sturfelt; Mary Anne Dooley; Graciela S Alarcón; Barri Fessler; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad Zoma; Munther Khamashta; Susan Manzi; Ronald van Vollenhoven; Manuel Ramos-Casals; Cynthia Aranow; Thomas Stoll Journal: J Rheumatol Date: 2014-04-01 Impact factor: 4.666
Authors: Brent W Kinder; Cyrus Shariat; Harold R Collard; Laura L Koth; Paul J Wolters; Jeffrey A Golden; Ralph J Panos; Talmadge E King Journal: Lung Date: 2010-04 Impact factor: 2.584
Authors: Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Ayodeji Adegunsoye; Justin M Oldham; Eleanor Valenzi; Cathryn Lee; Leah J Witt; Lena Chen; Steven Montner; Jonathan H Chung; Imre Noth; Rekha Vij; Mary E Strek; Aliya N Husain Journal: Arch Pathol Lab Med Date: 2017-05-03 Impact factor: 5.534
Authors: Ayodeji Adegunsoye; Justin M Oldham; Evans R Fernández Pérez; Mark Hamblin; Nina Patel; Mitchell Tener; Deepa Bhanot; Lacey Robinson; Sam Bullick; Lena Chen; Scully Hsu; Matthew Churpek; Donald Hedeker; Steven Montner; Jonathan H Chung; Aliya N Husain; Imre Noth; Mary E Strek; Rekha Vij Journal: ERJ Open Res Date: 2017-08-17
Authors: Ayodeji Adegunsoye; Justin M Oldham; Aliya N Husain; Lena Chen; Scully Hsu; Steven Montner; Jonathan H Chung; Rekha Vij; Imre Noth; Mary E Strek Journal: Front Med (Lausanne) Date: 2017-10-16
Authors: Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson Journal: Am J Respir Crit Care Med Date: 2020-08-01 Impact factor: 30.528